ADCT ADC Therapeutics SA

NYSE adctherapeutics.com


$ 4.26 $ 0.15 (3.65 %)    

Wednesday, 15-Oct-2025 15:59:54 EDT
QQQ $ 602.61 $ 4.22 (0.71 %)
DIA $ 463.04 $ 0.00 (0 %)
SPY $ 665.11 $ 2.94 (0.44 %)
TLT $ 90.76 $ -0.20 (-0.22 %)
GLD $ 387.41 $ 6.60 (1.73 %)
$ 4.26
$ 4.12
$ 4.00 x 300
$ 4.41 x 900
$ 4.10 - $ 4.37
$ 1.05 - $ 4.74
1,046,389
na
479.25M
$ 1.75
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2025 06-30-2025 10-Q
2 05-14-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-06-2024 03-31-2024 10-Q
7 03-13-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 top-5-biotech-stocks-with-strong-momentum

Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.

 guggenheim-reiterates-buy-on-adc-therapeutics-maintains-10-price-target

Guggenheim analyst Michael Schmidt reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $10 price target.

 adc-therapeutics-q2-adj-eps-025-beats-039-estimate-sales-18839m-beat-17776m-estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.39...

 rbc-capital-maintains-outperform-on-adc-therapeutics-lowers-price-target-to-5

RBC Capital analyst Leonid Timashev maintains ADC Therapeutics (NYSE:ADCT) with a Outperform and lowers the price target fro...

 adc-therapeutics-to-present-updated-data-from-phase-2-multicenter-iit-of-zynlonta-to-treat-rr-mzl-at-international-conference-on-malignant-lymphoma

Updated Phase 2 data evaluating ZYNLONTA® as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response...

 guggenheim-maintains-buy-on-adc-therapeutics-raises-price-target-to-10

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and raises the price target from $7 to ...

 adc-therapeutics-raises-100m-in-private-stock-deal-of-13m-shares-at-35share-and-warrants-to-purchase-157m-shares-at-343pre-funded-warrant-to-boost-cancer-drug-development

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

 adc-therapeutics-reports-93-response-rate-in-lymphoma-drug-trial-including-car-t-resistant-patients

ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), ...

 rbc-capital-reiterates-outperform-on-adc-therapeutics-maintains-8-price-target

RBC Capital analyst Gregory Renza reiterates ADC Therapeutics (NYSE:ADCT) with a Outperform and maintains $8 price target.

 adc-therapeutics-q1-adj-eps-022-beats-040-estimate-sales-2303m-beat-1771m-estimate

ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.40...

 adc-therapeutics-presents-data-from-lotis-7-phase-1b-clinical-trial-evaluating-zynlonta-in-combination-with-glofitamab-in-patients-with-rr-dlbcl

ZYNLONTA® plus glofitamab (COLUMVI®) demonstrated ORR of 95.5% and CR of 90.9%, among 22 evaluable patients with relapsed/refra...

 adc-therapeutics-claudin-6-targeting-adc-shows-strong-single-agent-and-combination-potential-in-solid-tumors

Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent antitumor activity in ovarian a...

 guggenheim-maintains-buy-on-adc-therapeutics-lowers-price-target-to-7

Guggenheim analyst Michael Schmidt maintains ADC Therapeutics (NYSE:ADCT) with a Buy and lowers the price target from $10 to...

 hc-wainwright--co-reiterates-buy-on-adc-therapeutics-maintains-8-price-target

HC Wainwright & Co. analyst Robert Burns reiterates ADC Therapeutics (NYSE:ADCT) with a Buy and maintains $8 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION